An activity level below 10% supports a TTP diagnosis but can also appear in severe sepsis and cancer, while the presence of ADAMTS13 inhibitors confirms that the cause of TTP is acquired [9]. Early diagnosis of TMA is crucial, as prompt identification and initiation of treatment significantly improve patient outcomes. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.